VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Keros Therapeutics, Inc. (KROS) Total Return Calculator with Dividends Reinvested

Keros Therapeutics, Inc.

Popular:

The total return for Keros Therapeutics, Inc. (KROS) stock is -15.10% over the past 12 months. So far it's down 37.22% this year. The 5-year total return is -78.08%, meaning $10,000 invested in KROS stock 5 years ago would be worth $2,192 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in KROS 1 year ago, it would be worth $8,490 today — you'd have lost $1,510.

With Dividends Reinvested$8,490-15.10%

Price Only (No DRIP)$8,490-15.10%

Period2025-05-07 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in KROS

1Y$8,490-$1,510 (-15.1%)-15.1% CAGR

3Y$2,701-$7,299 (-73.0%)-35.4% CAGR

5Y$2,192-$7,808 (-78.1%)-26.2% CAGR

10Y$5,797-$4,203 (-42.0%)-5.3% CAGR

15Y$5,797-$4,203 (-42.0%)-3.6% CAGR

20Y$5,797-$4,203 (-42.0%)-2.7% CAGR

30Y$5,797-$4,203 (-42.0%)-1.8% CAGR

Keros Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading KROS total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-37.22%	—	-37.22%	—	$6,278
1Y	-15.10%	-15.10%	-15.10%	—	$8,490
3Y	-72.99%	-35.36%	-72.99%	—	$2,701
5Y	-78.08%	-26.18%	-78.08%	—	$2,192
10Y	-42.03%	-5.31%	-42.03%	—	$5,797
15Y	-42.03%	-3.57%	-42.03%	—	$5,797
20Y	-42.03%	-2.69%	-42.03%	—	$5,797
30Y	-42.03%	-1.80%	-42.03%	—	$5,797

Risk & Highlights

Best Year+251.29%2020

Worst Year-63.30%2024

Max Drawdown-51.42%2025-12-10 → 2026-03-27

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-23.46%	-23.46%	—	+0.41%	-23.9pp
2025	+27.89%	+27.89%	—	+16.64%	+11.3pp
2024	-63.30%	-63.30%	—	+24.00%	-87.3pp
2023	-13.51%	-13.51%	—	+24.81%	-38.3pp
2022	-19.10%	-19.10%	—	-19.95%	+0.8pp

KROS underperformed the S&P 500 by 45.47pp over the past year (-15.10% vs +30.37%).

Loading summary...

KROS Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
KROSKeros Therapeutics, Inc.	$433M	-4.9%	-37.2%	-15.1%	—	-73.0%	-78.1%	-42.0%
IMVTImmunovant, Inc.	$5.5B	+10.6%	+5.1%	+96.1%	—	+40.9%	+62.4%	+173.6%
KRYSKrystal Biotech, Inc.	$8.7B	+12.4%	+20.2%	+116.9%	—	+238.5%	+319.2%	+2688.5%
DAWNDay One Biopharmaceuticals, Inc.	$2.2B	+0.3%	+143.3%	+241.7%	—	+65.1%	-8.4%	-8.4%
BEAMBeam Therapeutics Inc.	$3.2B	+28.5%	+16.0%	+93.9%	—	-5.6%	-55.6%	+67.8%
FOLDAmicus Therapeutics, Inc.	$4.5B	+0.1%	+1.5%	+137.9%	—	+19.0%	+48.6%	+119.2%
SMMTSummit Therapeutics Inc.	$13.3B	-10.8%	-2.1%	-29.4%	—	+784.0%	+194.7%	+91.6%
RAREUltragenyx Pharmaceutical Inc.	$2.6B	+12.9%	+10.7%	-21.8%	—	-44.5%	-77.2%	-59.4%
IONSIonis Pharmaceuticals, Inc.	$12.6B	+2.9%	-4.6%	+129.9%	—	+116.1%	+108.0%	+121.1%
PTCTPTC Therapeutics, Inc.	$5.3B	-7.3%	-16.0%	+58.2%	—	+16.1%	+60.3%	+733.2%
SRPTSarepta Therapeutics, Inc.	$2.2B	-9.9%	-2.4%	-43.4%	—	-83.6%	-72.1%	+18.0%

Compare:KROS vs IMVT KROS vs KRYS KROS vs DAWN KROS vs IMVT vs KRYS

About KROS Dividend Returns

Keros Therapeutics, Inc. (KROS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of KROS over the past year?

Keros Therapeutics, Inc. (KROS) delivered a return of -15.10% over the past year. Since KROS does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in KROS be worth today?

A $10,000 investment in Keros Therapeutics, Inc. one year ago would be worth $8,490 today, representing a loss of $1,510.

Q3Does KROS pay dividends?

Keros Therapeutics, Inc. (KROS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For KROS, the total return equals the price-only return.

Q4Did KROS beat the S&P 500?

No, Keros Therapeutics, Inc. (KROS) underperformed the S&P 500 by 45.47 percentage points over the past year. KROS delivered a total return of -15.10%, compared to the S&P 500's 30.37%. This means a passive S&P 500 index fund outperformed KROS by 45.47pp during this period.

Q5What is KROS's worst drawdown?

Keros Therapeutics, Inc. (KROS) experienced a maximum drawdown of -51.42% over the past year, declining from its peak on 2025-12-10 to its trough on 2026-03-27. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is KROS's long-term total return over 10, 20, or 30 years?

Here are Keros Therapeutics, Inc. (KROS)'s long-term returns with dividends reinvested. Over 10 years, the total return is -42.0% (-5.3% CAGR) — $10,000 would have grown to $5,797. Over 20 years: -42.0% total return (-2.7% CAGR) — $10,000 → $5,797. Over 30 years: -42.0% total return (-1.8% CAGR) — $10,000 → $5,797. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was KROS's best and worst year?

Keros Therapeutics, Inc.'s best calendar year was 2020 with a total return of 251.3%. Its worst year was 2024 with a total return of -63.3%. This range shows the volatility investors should expect — the difference between the best and worst year is 314.6 percentage points.